ATE475418T1 - O-methylierte rapamycinderivate zur milderung oder vermeidung lymphoproliferativer erkrankungen - Google Patents
O-methylierte rapamycinderivate zur milderung oder vermeidung lymphoproliferativer erkrankungenInfo
- Publication number
- ATE475418T1 ATE475418T1 AT01903095T AT01903095T ATE475418T1 AT E475418 T1 ATE475418 T1 AT E475418T1 AT 01903095 T AT01903095 T AT 01903095T AT 01903095 T AT01903095 T AT 01903095T AT E475418 T1 ATE475418 T1 AT E475418T1
- Authority
- AT
- Austria
- Prior art keywords
- reducing
- rapamycin derivatives
- lymphoproliferative diseases
- mammal
- preventing
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical class C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title 1
- 230000001589 lymphoproliferative effect Effects 0.000 title 1
- 241000124008 Mammalia Species 0.000 abstract 3
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 206010027476 Metastases Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000001926 lymphatic effect Effects 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 abstract 1
- 229960002930 sirolimus Drugs 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/5052—Cells of the immune system involving B-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17608600P | 2000-01-14 | 2000-01-14 | |
| PCT/US2001/001537 WO2001051049A1 (en) | 2000-01-14 | 2001-01-12 | O-methylated rapamycin derivatives for alleviation and inhibition of lymphoproliferative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE475418T1 true ATE475418T1 (de) | 2010-08-15 |
Family
ID=22642913
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01903095T ATE475418T1 (de) | 2000-01-14 | 2001-01-12 | O-methylierte rapamycinderivate zur milderung oder vermeidung lymphoproliferativer erkrankungen |
Country Status (9)
| Country | Link |
|---|---|
| US (5) | US7754734B2 (de) |
| EP (2) | EP2298299A3 (de) |
| JP (3) | JP2003519655A (de) |
| AT (1) | ATE475418T1 (de) |
| AU (2) | AU2001230956B2 (de) |
| CA (1) | CA2397354C (de) |
| DE (1) | DE60142677D1 (de) |
| ES (1) | ES2349458T3 (de) |
| WO (1) | WO2001051049A1 (de) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6890546B2 (en) | 1998-09-24 | 2005-05-10 | Abbott Laboratories | Medical devices containing rapamycin analogs |
| ATE475418T1 (de) * | 2000-01-14 | 2010-08-15 | Univ Pennsylvania | O-methylierte rapamycinderivate zur milderung oder vermeidung lymphoproliferativer erkrankungen |
| AU2011226833B9 (en) * | 2001-02-19 | 2014-07-03 | Novartis Ag | Cancer treatment |
| DK3351246T3 (da) * | 2001-02-19 | 2019-06-03 | Novartis Pharma Ag | Rapamycinderivat til behandling af en solid tumor, som er associeret med dereguleret angionese |
| US6939376B2 (en) * | 2001-11-05 | 2005-09-06 | Sun Biomedical, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
| US7682387B2 (en) * | 2002-04-24 | 2010-03-23 | Biosensors International Group, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
| US20040024450A1 (en) * | 2002-04-24 | 2004-02-05 | Sun Biomedical, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
| US7169404B2 (en) * | 2003-07-30 | 2007-01-30 | Advanced Cardiovasular Systems, Inc. | Biologically absorbable coatings for implantable devices and methods for fabricating the same |
| US7901451B2 (en) | 2004-09-24 | 2011-03-08 | Biosensors International Group, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
| US20080097591A1 (en) | 2006-10-20 | 2008-04-24 | Biosensors International Group | Drug-delivery endovascular stent and method of use |
| US8067055B2 (en) * | 2006-10-20 | 2011-11-29 | Biosensors International Group, Ltd. | Drug-delivery endovascular stent and method of use |
| US20080103584A1 (en) * | 2006-10-25 | 2008-05-01 | Biosensors International Group | Temporal Intraluminal Stent, Methods of Making and Using |
| KR100930167B1 (ko) * | 2007-09-19 | 2009-12-07 | 삼성전기주식회사 | 초광각 광학계 |
| US20110098241A1 (en) * | 2008-04-14 | 2011-04-28 | Poniard Pharmaceuticals, Inc. | Rapamycin analogs as anti-cancer agents |
| PT2365802T (pt) | 2008-11-11 | 2017-11-14 | Univ Texas | Microcápsulas de rapamicina e utilização para o tratamento de cancro |
| US9283211B1 (en) | 2009-11-11 | 2016-03-15 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
| CN102268015B (zh) * | 2011-08-30 | 2013-08-28 | 成都摩尔生物医药有限公司 | 一种依维莫司的合成方法 |
| US20150290176A1 (en) | 2012-10-12 | 2015-10-15 | The Board Of Regents Of The University Of Texas System | Use of mtor inhibitors to treat vascular cognitive impairment |
| EP2968281B1 (de) | 2013-03-13 | 2020-08-05 | The Board of Regents of The University of Texas System | Mtor-hemmer zur vorbeugung von darmpolypenwachstum |
| DK3089737T3 (da) | 2013-12-31 | 2021-12-13 | Rapamycin Holdings Llc | Orale rapamycin-nanopartikelpræparater og anvendelse. |
| US9700544B2 (en) | 2013-12-31 | 2017-07-11 | Neal K Vail | Oral rapamycin nanoparticle preparations |
| CA2968049A1 (en) | 2014-04-16 | 2015-10-22 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
| CN105254646A (zh) * | 2014-05-28 | 2016-01-20 | 上海博邦医药科技有限公司 | 一种制备依维莫司的方法 |
| WO2016117431A1 (ja) | 2015-01-19 | 2016-07-28 | 学校法人慶應義塾 | 内耳性難聴治療薬 |
| AU2018219317A1 (en) * | 2017-02-10 | 2019-09-26 | Mount Tam Therapeutics, Inc. | Rapamycin analog |
| EP3624863B1 (de) | 2017-05-15 | 2021-04-14 | C.R. Bard, Inc. | Medizinische vorrichtung mit wirkstofffreisetzender beschichtung und zwischenschicht |
| JP7262581B2 (ja) | 2018-11-14 | 2023-04-21 | ルトニックス，インコーポレーテッド | 改質されたデバイス表面に薬物溶出コーティングを有する医療用デバイス |
| CN109776571B (zh) * | 2019-01-31 | 2021-06-11 | 哈药慈航制药股份有限公司 | 一种雷帕霉素类似物及其制备方法和应用 |
| JP7487228B2 (ja) | 2019-04-08 | 2024-05-20 | バード・ペリフェラル・バスキュラー・インコーポレーテッド | 改質されたデバイス表面に薬物溶出コーティングを有する医療用デバイス |
| CN110917194A (zh) * | 2019-11-07 | 2020-03-27 | 福建省微生物研究所 | 雷帕霉素噻唑类衍生物在制备抗阿尔茨海默症药物中的应用 |
| CN113653305B (zh) * | 2021-09-07 | 2024-11-05 | 中国五冶集团有限公司 | 一种电动顶升操作平台 |
| CN115323915B (zh) * | 2022-10-17 | 2023-01-06 | 广州市市政工程试验检测有限公司 | 一种桥梁索杆检测与修复机器人 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5206018A (en) * | 1978-11-03 | 1993-04-27 | Ayerst, Mckenna & Harrison, Inc. | Use of rapamycin in treatment of tumors |
| US4401653A (en) * | 1981-03-09 | 1983-08-30 | Ayerst, Mckenna & Harrison Inc. | Combination of rapamycin and picibanil for the treatment of tumors |
| US4699783A (en) * | 1983-03-11 | 1987-10-13 | Terman David S | Products and methods for treatment of cancer |
| ES2084940T3 (es) * | 1991-06-18 | 1996-05-16 | American Home Prod | Uso de la rapamicina para el tratamiento de la leucemia/linfoma de las celulas t adultas. |
| GB9221220D0 (en) * | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
| US5258389A (en) * | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
| US5527907A (en) * | 1993-11-19 | 1996-06-18 | Abbott Laboratories | Macrolide immunomodulators |
| US5525610A (en) * | 1994-03-31 | 1996-06-11 | American Home Products Corporation | 42-Epi-rapamycin and pharmaceutical compositions thereof |
| ES2193379T3 (es) * | 1996-06-11 | 2003-11-01 | Novartis Ag | Combinacion de un analogo de somatostatina y de una rapamicina. |
| JP3352411B2 (ja) * | 1998-03-05 | 2002-12-03 | 株式会社東芝 | 制御システム、電力系統保護制御システムおよびプログラムを記憶した記憶媒体 |
| JP2002544167A (ja) | 1999-05-10 | 2002-12-24 | ノバルティス アクチエンゲゼルシャフト | 有機化合物 |
| ATE475418T1 (de) * | 2000-01-14 | 2010-08-15 | Univ Pennsylvania | O-methylierte rapamycinderivate zur milderung oder vermeidung lymphoproliferativer erkrankungen |
| ATE411321T1 (de) * | 2000-09-19 | 2008-10-15 | Wyeth Corp | Wasserlösliche rapamycin-ester |
| US6399625B1 (en) * | 2000-09-27 | 2002-06-04 | Wyeth | 1-oxorapamycins |
| US6440991B1 (en) * | 2000-10-02 | 2002-08-27 | Wyeth | Ethers of 7-desmethlrapamycin |
| US6399626B1 (en) * | 2000-10-02 | 2002-06-04 | Wyeth | Hydroxyesters of 7-desmethylrapamycin |
-
2001
- 2001-01-12 AT AT01903095T patent/ATE475418T1/de not_active IP Right Cessation
- 2001-01-12 EP EP10007811A patent/EP2298299A3/de not_active Withdrawn
- 2001-01-12 WO PCT/US2001/001537 patent/WO2001051049A1/en not_active Ceased
- 2001-01-12 EP EP01903095A patent/EP1250135B1/de not_active Expired - Lifetime
- 2001-01-12 CA CA2397354A patent/CA2397354C/en not_active Expired - Lifetime
- 2001-01-12 DE DE60142677T patent/DE60142677D1/de not_active Expired - Lifetime
- 2001-01-12 AU AU2001230956A patent/AU2001230956B2/en not_active Expired
- 2001-01-12 AU AU3095601A patent/AU3095601A/xx active Pending
- 2001-01-12 ES ES01903095T patent/ES2349458T3/es not_active Expired - Lifetime
- 2001-01-12 JP JP2001551473A patent/JP2003519655A/ja not_active Withdrawn
-
2002
- 2002-07-09 US US10/192,193 patent/US7754734B2/en not_active Expired - Lifetime
-
2007
- 2007-09-07 US US11/899,673 patent/US7781447B2/en not_active Expired - Fee Related
-
2008
- 2008-01-04 JP JP2008000081A patent/JP5184894B2/ja not_active Expired - Lifetime
-
2009
- 2009-11-27 JP JP2009269988A patent/JP5180177B2/ja not_active Expired - Lifetime
-
2010
- 2010-06-07 US US12/795,335 patent/US8569332B2/en not_active Expired - Fee Related
- 2010-06-09 US US12/797,085 patent/US8759370B2/en not_active Expired - Fee Related
- 2010-07-06 US US12/830,883 patent/US8778961B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1250135A1 (de) | 2002-10-23 |
| HK1050145A1 (en) | 2003-06-13 |
| US20080182867A9 (en) | 2008-07-31 |
| EP2298299A2 (de) | 2011-03-23 |
| AU2001230956B2 (en) | 2005-08-18 |
| WO2001051049A1 (en) | 2001-07-19 |
| US20100290994A1 (en) | 2010-11-18 |
| DE60142677D1 (de) | 2010-09-09 |
| US7754734B2 (en) | 2010-07-13 |
| WO2001051049A9 (en) | 2003-01-16 |
| US20100305151A1 (en) | 2010-12-02 |
| EP1250135B1 (de) | 2010-07-28 |
| JP2010090131A (ja) | 2010-04-22 |
| CA2397354C (en) | 2011-07-19 |
| AU3095601A (en) | 2001-07-24 |
| US20080125457A1 (en) | 2008-05-29 |
| CA2397354A1 (en) | 2001-07-19 |
| US8759370B2 (en) | 2014-06-24 |
| ES2349458T3 (es) | 2011-01-03 |
| JP2003519655A (ja) | 2003-06-24 |
| JP5180177B2 (ja) | 2013-04-10 |
| US8778961B2 (en) | 2014-07-15 |
| JP5184894B2 (ja) | 2013-04-17 |
| US8569332B2 (en) | 2013-10-29 |
| US20110104304A1 (en) | 2011-05-05 |
| EP1250135A4 (de) | 2006-06-07 |
| EP2298299A3 (de) | 2012-02-29 |
| US20040010002A1 (en) | 2004-01-15 |
| US7781447B2 (en) | 2010-08-24 |
| JP2008106074A (ja) | 2008-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE475418T1 (de) | O-methylierte rapamycinderivate zur milderung oder vermeidung lymphoproliferativer erkrankungen | |
| ATE320803T1 (de) | Verfahren zur behandlung von alzheimerschen krankheit | |
| IL162447A0 (en) | Methods for slowing senescence and treating and preventing diseases associated with senescence | |
| ATE259215T1 (de) | Zusammensetzung zur regulierung des hauterscheinungsbildes | |
| ATE348829T1 (de) | Pharmazeutische zusammensetzungen zur behandlung von störungen des zns oder anderen erkrankungen | |
| PT971713E (pt) | Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao | |
| CY1108706T1 (el) | Ανοσορυθμιστης | |
| MXPA04004714A (es) | Derivados de aril 1,4-pirazina sustituidos. | |
| MY130489A (en) | Substituted aryl 1, 4-pyrazine derivatives | |
| BR0114054A (pt) | Método para tratar alergias usando pirazóis substituìdos | |
| EA200401365A1 (ru) | Способы лечения илеуса | |
| EP1581629A4 (de) | Verfahren zur identifizierung,beurteilung und behandlung von patienten mit einerproteasomeninhibitionstherapie | |
| CY1112932T1 (el) | Αναστολεις sμαd7 για τη θεραπευτικη αγωγη ασθενειων του κνς | |
| UA70925C2 (uk) | Спосіб лікування естрогенстимульованого раку | |
| TW200505829A (en) | Protease inhibitors for coronaviruses and sars-cov and the use thereof | |
| EP1505990A4 (de) | Verfahren zur behandlung von hepatitis | |
| NO20026222L (no) | Fremgangsmåte til å behandle neutrofilrelaterte sykdommer med topiske anestesimidler | |
| BR9912327A (pt) | Inibidores da uroquinase | |
| EE200300366A (et) | Meetodid nahahaiguste ravimiseks või tõkestamiseks CD2-siduvate vahendite abil | |
| DE60228567D1 (de) | Behandlung von hyperlipidämie | |
| BRPI0411864A (pt) | combinação de inibidores de src quinase e agentes quimioterápicos para o tratamento de doenças proliferativas | |
| AU5576601A (en) | Methods for preventing and treating alopecia induced by chemotherapy or radiotherapy | |
| BR0309009A (pt) | Método para o tratamento de hipersecreção de muco | |
| EP1419236A4 (de) | Verfahren zur behandlung von sklerotischen erkrankungen unter verwendung cd2-bindender substanzen | |
| BR0111785A (pt) | Composições e métodos para tratamento de candidìase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |